Tarsus Pharmaceuticals logo
Tarsus Pharmaceuticals
TARS | NASDAQ
Chart Builder DCF Calculator
$78.68
-$1.60 (-1.99%)
At close: Nov 16, 2026, 4:00 PM ET
$78.16
-$0.52 (-0.66%)
After-hours: Nov 16, 2026, 7:30 PM ET

Tarsus Pharmaceuticals Company Profile

Company profile explained

Company Profile

Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to advancing and commercializing innovative therapies, primarily focusing on ocular conditions. Its leading investigational drug, TP-03, a novel treatment currently in Phase III trials, is being developed to address blepharitis specifically caused by Demodex mite infestations, as well as meibomian gland disease. Beyond this, Tarsus is also progressing TP-04 for rosacea and TP-05, which targets Lyme disease prevention and aims to reduce community-level malaria. A core element of its development strategy involves lotilaner, a compound utilized to tackle a variety of human diseases across diverse therapeutic areas, encompassing eye care, dermatology, and other medical fields. Established in 2016, the company maintains its headquarters in Irvine, California.

Key Executives

Name Position
Bobak R. Azamian Co-Founder, President, Chief Executive Officer & Chairman
Jeffrey S. Farrow Chief Financial Officer & Chief Strategy Officer
Seshadri Neervannan Chief Operating Officer
Adrienne Kemp Vice President of Corporate Communications
Bryan Wahl General Counsel & Corporate Secretary
Cara Miller Senior Vice President of Corporate Affairs
David Nakasone Head of Investor Relations
Dianne C. Whitfield Chief Human Resources Officer
Elizabeth Yeu Chief Medical Officer
Matthew Rossen Vice President of Marketing
Scott Youmans Vice President of Sales

Latest SEC Filings

Date Type Title
Oct 13, 2026 S-3ASR Automatic shelf registration statement of securiti...
Oct 13, 2026 S-3ASR Automatic shelf registration statement of securiti...
Oct 13, 2026 8-K/A [Amend] Current Report
Sep 17, 2026 4 Filing
Sep 17, 2026 4 Filing
Sep 17, 2026 4 Filing
Sep 10, 2026 8-K Current Report
Sep 09, 2026 4 Filing
Sep 09, 2026 4 Filing
Sep 09, 2026 4 Filing
View All SEC Filings ➞
Tarsus Pharmaceuticals
Tarsus Pharmaceuticals logo
Country United States
IPO Date Oct 16, 2020
Industry Biotechnology
Sector Healthcare
Employees 370
CEO Bobak R. Azamian

Contact Details

15440 Laguna Canyon Road Irvine, California 92618 United States

Stock Details

Ticker Symbol TARS
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001819790
CUSIP Number 87650L103
ISIN Number US87650L1035
SIC Code 2836

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.